Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xinyi Powder in the Treatment of Allergic Rhinitis With Lung Deficiency and Cold Syndrome
NCT07899515Terminated
- Sponsor
- Nanjing University of Chinese Medicine
- Start
- Oct 2024
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Randomised, double-blind trial in allergic rhinitis (AR) comparing Xinyi Powder Placebo Group with Xinyi Powder Group (2 arms). Primary endpoint: Total Nasal Symptom Score at Day 14. Started Oct 2024; status: terminated.
02
Drugs
Xinyi Powder
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT07899515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07899515.